Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock was up 15.10 in the premarket after jumping close to 60% in the previous close. The company’s stock has changed by 138.40% in the past five days and 60.22% in the past three months. At the time of publication, ATOS shares are trading 213.68% higher than they did a year ago, and the market performance over the past 12 months is up 92.26%.
Most recent development…
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The Atossa Therapeutics, Inc. has recently announced that Dr. Steven C. Quay, President, and CEO of the company, will be a panelist at the 2021 precision medicine world conference “21st-century precision medicine in the era of COVID-19.” The conference will be held virtually from January 25-27, 2021.
- FAANG Stocks: Which 3 stocks are the best to Invest in 2021
- 3 Best Telehealth Stocks to Watch For in 2021
The development of new SARS-CoV-2 therapeutics will be the panel’s topic, which will start at 11:30 am PST on January 26, 2021.
The keynote speaker for the event will be Dr. Anthony S. Fauci. In addition to being the U.S. National Institute of Allergy and Infectious Diseases (NIH), Dr. Fauci is also the Chief Medical Advisor to the President.
The Precision Medicine World Conference, or PMWC, is a unique forum for precision medicine. Healthcare and Biotechnology experts from across the globe attend PMWC. Through the conference, practical content is presented to bridge the knowledge gap between different sectors, thereby catalyzing cross-sector collaboration to progress personalized medicine.
Further details about PMWC and how to register can be found at https://www.pmwcintl.com/covid/.
In most cases, investors monitor the activities of insider traders to make decisions. We can see from Atossa Therapeutics Inc.’s ownership summary that Institutional holders make up 4.20% of its total stock ownership. Combined, they hold 10.16 million shares. Looking at the three largest shareholders, Sabby Capital LLC owns 0.5 million shares. The Vanguard Group, Inc. owns 0.12 million shares in the second place, and Anson Funds Management LP is in third place with 0.1 million shares.